Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials

PURPOSE: Non-alcoholic fatty liver disease (NAFLD) affects about 75% of patients with type 2 diabetes mellitus (T2DM). We conducted a meta-analysis to determine the effect of canagliflozin on fatty liver indexes in T2DM patients. METHODS: A literature search of PubMed, Embase and Cochrane was condu...

Full description

Bibliographic Details
Main Authors: Boyu Li, Ying Wang, Zhikang Ye, Hui Yang, Xiangli Cui, Zhenjun Wang, Lihong Liu
Format: Article
Language:English
Published: Canadian Society for Pharmaceutical Sciences 2018-06-01
Series:Journal of Pharmacy & Pharmaceutical Sciences
Online Access:https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/29831
id doaj-e6ad2d3c0b534a3d91899f943dd8a93b
record_format Article
spelling doaj-e6ad2d3c0b534a3d91899f943dd8a93b2020-11-25T03:36:08ZengCanadian Society for Pharmaceutical SciencesJournal of Pharmacy & Pharmaceutical Sciences1482-18262018-06-0121110.18433/jpps29831Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled TrialsBoyu Li0Ying Wang1Zhikang Ye2Hui Yang3Xiangli Cui4Zhenjun Wang5Lihong Liu6Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.Department of General Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. PURPOSE: Non-alcoholic fatty liver disease (NAFLD) affects about 75% of patients with type 2 diabetes mellitus (T2DM). We conducted a meta-analysis to determine the effect of canagliflozin on fatty liver indexes in T2DM patients. METHODS: A literature search of PubMed, Embase and Cochrane was conducted up to March 30, 2017. The liver function test and lipid profile were extracted from randomized controlled trials (RCTs) to evaluate the effect of canagliflozin on fatty liver. Weighted mean differences (WMDs) or relative risks and 95% confidence intervals (CIs) were computed by using either fixed or random-effects models. Sensitivity analysis and publication bias were evaluated. RESULTS: Our results showed that canagliflozin decreased serum concentrations of  alanine amino transferase (WMD: -11.68 [95% CI: -18.95, -10.95]; P<0.001), aspartate amino transferase (WMD: -7.50 [95% CI: -10.61, -4.38]; P<0.001), gamma-glutamyl transferase (WMD: -15.17 [95% CI: -17.73, -12.61]; P<0.001), triglycerides (WMD: -0.10 [95% CI: -0.15, -0.05]; P<0.001) but increased low-density lipoprotein cholesterol (WMD: 0.1 [95% CI: 0.06, 0.13]; P<0.001), high-density lipoprotein cholesterol (WMD: 0.06 [95% CI: 0.05, 0.07]; P<0.001) at week 26 or 52. CONCLUSIONS: Our results indicated that canagliflozin may have a protective effect on fatty liver in T2DM patients. The limitation was that the liver biopsy was hard to obtain in published studies. More RCTs specified on NAFLD are needed to get further information.   This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/29831
collection DOAJ
language English
format Article
sources DOAJ
author Boyu Li
Ying Wang
Zhikang Ye
Hui Yang
Xiangli Cui
Zhenjun Wang
Lihong Liu
spellingShingle Boyu Li
Ying Wang
Zhikang Ye
Hui Yang
Xiangli Cui
Zhenjun Wang
Lihong Liu
Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
Journal of Pharmacy & Pharmaceutical Sciences
author_facet Boyu Li
Ying Wang
Zhikang Ye
Hui Yang
Xiangli Cui
Zhenjun Wang
Lihong Liu
author_sort Boyu Li
title Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
title_short Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
title_full Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
title_fullStr Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
title_full_unstemmed Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
title_sort effects of canagliflozin on fatty liver indexes in patients with type 2 diabetes: a meta-analysis of randomized controlled trials
publisher Canadian Society for Pharmaceutical Sciences
series Journal of Pharmacy & Pharmaceutical Sciences
issn 1482-1826
publishDate 2018-06-01
description PURPOSE: Non-alcoholic fatty liver disease (NAFLD) affects about 75% of patients with type 2 diabetes mellitus (T2DM). We conducted a meta-analysis to determine the effect of canagliflozin on fatty liver indexes in T2DM patients. METHODS: A literature search of PubMed, Embase and Cochrane was conducted up to March 30, 2017. The liver function test and lipid profile were extracted from randomized controlled trials (RCTs) to evaluate the effect of canagliflozin on fatty liver. Weighted mean differences (WMDs) or relative risks and 95% confidence intervals (CIs) were computed by using either fixed or random-effects models. Sensitivity analysis and publication bias were evaluated. RESULTS: Our results showed that canagliflozin decreased serum concentrations of  alanine amino transferase (WMD: -11.68 [95% CI: -18.95, -10.95]; P<0.001), aspartate amino transferase (WMD: -7.50 [95% CI: -10.61, -4.38]; P<0.001), gamma-glutamyl transferase (WMD: -15.17 [95% CI: -17.73, -12.61]; P<0.001), triglycerides (WMD: -0.10 [95% CI: -0.15, -0.05]; P<0.001) but increased low-density lipoprotein cholesterol (WMD: 0.1 [95% CI: 0.06, 0.13]; P<0.001), high-density lipoprotein cholesterol (WMD: 0.06 [95% CI: 0.05, 0.07]; P<0.001) at week 26 or 52. CONCLUSIONS: Our results indicated that canagliflozin may have a protective effect on fatty liver in T2DM patients. The limitation was that the liver biopsy was hard to obtain in published studies. More RCTs specified on NAFLD are needed to get further information.   This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.
url https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/29831
work_keys_str_mv AT boyuli effectsofcanagliflozinonfattyliverindexesinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials
AT yingwang effectsofcanagliflozinonfattyliverindexesinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials
AT zhikangye effectsofcanagliflozinonfattyliverindexesinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials
AT huiyang effectsofcanagliflozinonfattyliverindexesinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials
AT xianglicui effectsofcanagliflozinonfattyliverindexesinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials
AT zhenjunwang effectsofcanagliflozinonfattyliverindexesinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials
AT lihongliu effectsofcanagliflozinonfattyliverindexesinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials
_version_ 1724550904779112448